Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study

Table 6 Clinical features associated with biological DMARD use

Clinical feature^a	N(%)^b	Odds ratio for bDMARD use (95% CI)
High-titer rheumatoid factor^c	616 (56.1)	1.45 (1.12–1.86)
Interstitial pneumonia^d	42 (3.8)	1.84 (0.99–3.42)
Erosive disease^e	602 (54.9)	1.47 (1.14–1.89)
Cutaneous vasculitis	13 (1.2)	4.12 (1.26–13.47)
Subcutaneous nodules	92 (8.3)	1.73 (1.13–2.66)

^a Groups of patients with and without each feature were compared (binary logistic regression); p < 0.05 for all comparisons. ^b Total numbers and percentage of patients with the clinical feature among all those assessed for that condition. ^c Defined as at least 3 times the upper limit of normality ^d Defined by findings suggestive of interstitial X-ray disease: ground-glass opacities, fibrosis compatible lesions (honeycombing, traction bronchiectasis / bronchiolectasis, irregular interlobular septal thickening, and irregular interfaces) ^e Defined as at least 3 erosions in some specified joints (see methodology)

ISSN: 2523-3106